Source: Contract Pharma

Yposkesi: Yposkesi Launches LentiSure Lentiviral Vector Production Platform

New LV platform provides CAR-T developers with more robust capacity for clinical development and commercial cell and gene therapy pipelines.

Read full article »
Yposkesi's Competitors | Yposkesi's News | Yposkesi's Financials
Stay up-to-date with the latest news on Yposkesi
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Alain Lamproye's photo - Chairman & CEO of Yposkesi

Chairman & CEO

Alain Lamproye

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Yposkesi